Current status of hepatocellular carcinoma treatment in Japan: Hepatic arterial infusion chemotherapy

Clinical Drug Investigation

Volumn 32, Issue SUPPL. 2, 2012, Pages 15-23

  Yamashita, Tatsuya ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; IODINATED POPPYSEED OIL; RECOMBINANT INTERFERON; SORAFENIB;

ABDOMINAL PAIN; ADVANCED CANCER; ARTERY OCCLUSION; ARTIFICIAL EMBOLISM; BACKACHE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CATHETER COMPLICATION; CATHETER INFECTION; CATHETER OCCLUSION; CATHETER THROMBOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMATOMA; HEPATIC ARTERY; HEPATIC ARTERY INFUSION CHEMOTHERAPY; HUMAN; JAPAN; LIVER ARTERIOGRAPHY; LIVER CELL CARCINOMA; LIVER RESECTION; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PEPTIC ULCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; STOMACH ULCER; STROKE; SURVIVAL TIME; TREATMENT RESPONSE; VASCULITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; JAPAN; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PYRIDINES;

EID: 84864681330     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1163022-S0-000000000-00000     Document Type: Review

References (54)

1. Kudo M. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010; 25 (3): 439-52
2. Ganeshan A, Upponi S, Hon LQ, et al. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008; 19 (5): 847-51 (Pubitemid 351627299)
3. Ikai I, Itai Y, Okita K, et al. Report of the 15th Follow-up Survey of Primary Liver Cancer. Hepatol Res 2004; 28 (1): 21-9 (Pubitemid 38145784)
4. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006; 12 (5): 828-9 (Pubitemid 43380776)
5. Ikai I, Arii S, Ichida T, et al. Report of the 16th Follow-up Survey of Primary Liver Cancer. Hepatol Res 2005; 32 (3): 163-72 (Pubitemid 41070387)
6. Ikai I, Arii S, Okazaki M, et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37 (9): 676-91 (Pubitemid 47054774)
7. Ikai I, Kudo M, Arii S, et al. Report of the 18th Follow-up Survey of Primary Liver Cancer in Japan. Hepatology Research 2010; 40 (11): 1043-59
8. Yoshio Y, Shigeki A, Kyoichi I, et al. Survey and follow-up study of primary liver cancer in Japan. Report 14. Acta Hepatologica Japonica 2000; 41 (12): 799-811
9. The Japan Society of Hepatology. The Japanese HCC Clinical Practice Guideline. Treatment algorithm for hepatocellular carcinoma. Hepatology Research 2010; 40 Suppl. 1: 8-9
10. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399): 1907-17 (Pubitemid 37518510)
11. Bruix J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma: an update [online]. Available from URL: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guide lines/HCCUpdate2010.pdf [Accessed 2011 Jan 25]
12. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: hepatobiliary cancers V.2.2012 [online]. Available from URL: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp [Accessed 2012 Feb 09]
13. The Japan Society of Hepatology. The Japanese HCC Clinical Practice Guideline. Chapter 4: Chemotherapy and radiotherapy. Hepatology Research 2010; 40 Suppl. 1: 74-95
14. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, et al. Intra-arterial versus systemic chemotherapy for nonoperable hepatocellular carcinoma. Hepatogastroenterology 1999; 46 (26): 1122-5 (Pubitemid 29224804)
15. Kudo M, Arii S, Ikai I, et al. Report of the 17th Follow-up Survey of Primary Liver Cancer (in Japanese). Kyoto: Media Planning, 2006
16. Yamaoka Y, Ikai I, Itai Y, et al. Liver Cancer Study Group Japan. Survey and follow-up study of primary liver cancer in Japan - Report 15 (in Japanese). Kanzo 2003; 44: 157-75
17. Yamaoka Y, Arii S, Inoue K, et al. Liver Cancer Study Group of Japan Survey and follow-up study of primary liver cancer in Japan - Report 14 (in Japanese). Kanzo 2000; 41: 799-811
18. Yamaoka Y, Ikai I, Arii S, et al. Liver Cancer Study Group of Japan. Report of the 16th Follow-up Survey of Primary Liver Cancer (2000-2001) (in Japanese). Kanzo 2005; 46: 234-54
19. Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010; 78 Suppl. 1: 148-53
20. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95 (3): 588-95 (Pubitemid 34810185)
21. Eun JR, Lee HJ, Moon HJ, et al. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 2009; 44 (12): 1477-86
22. Lai YC, Shih CY, Jeng CM, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003; 9 (12): 2666-70
23. Naganuma A, Toyoda M, Hamada T, et al. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. Gan To Kagaku Ryoho 2007; 34 (5): 729-34
24. Okuda K, Tanaka M, Shibata J, et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999; 6 (3): 587-91
25. Park JY, Ahn SH, Yoon YJ, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110 (1): 129-37
26. Sumie S, Yamashita F, Ando E, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003; 181 (5): 1327-34 (Pubitemid 37296411)
27. Tanioka H, Tsuji A, Morita S, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23 (2C): 1891-7 (Pubitemid 36750863)
28. Kim BK, Park JY, Choi HJ, et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 137 (4): 659-67 [Epub 2010 Jun 16]
29. Cheong JY, Lee KM, Cho SW, et al. Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 2005; 32 (2): 127-33 (Pubitemid 40945773)
30. Murata K, Shiraki K, Kawakita T, et al. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 2003; 23 (2C): 1719-22 (Pubitemid 36750837)
31. Yamasaki T, Kimura T, Kurokawa F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40 (1): 70-8 (Pubitemid 40796335)
32. Yamasaki T, Kurokawa F, Takami T, et al. Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective? Hepatol Res 2003; 27 (1): 36-44 (Pubitemid 37168650)
33. Nagamatsu H, Hiraki M, Mizukami N, et al. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther 2010; 32 (4): 543-50
34. Enjoji M, Morizono S, Kotoh K, et al. Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. World J Gastroenterol 2005; 11 (36): 5685-7 (Pubitemid 41684924)
35. Hirooka M, Koizumi Y, Kisaka Y, et al. Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus. AJR Am J Roentgenol 2010; 194 (2): W221-6
36. Kuroda M, Kobayashi Y, Urawa N, et al. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. Hepatogastroenterology 2007; 54 (74): 518-21 (Pubitemid 46724719)
37. Nagano H, Miyamoto A, Wada H, et al. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, andmultiple nodules. Cancer 2007; 110 (11): 2493-501 (Pubitemid 350174935)
38. Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106 (9): 1990-7 (Pubitemid 43673215)
39. Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93 (5): 557-64 (Pubitemid 43079999)
40. Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94 (2): 435-42 (Pubitemid 34081374)
41. Uka K, Aikata H, Takaki S, et al. Similar effects of recombinant interferon-alpha-2b and natural interferonalpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007; 27 (9): 1209-16 (Pubitemid 47543149)
42. Uka K, Aikata H, Takaki S, et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42 (10): 845-53 (Pubitemid 47617463)
43. Baba H, Matsumoto G, Tsuruta K, et al. [Successful hepatic arterial infusion therapy of CDDP/5-FU/IFN-beta3 for recurrent hepatocellular carcinoma]. Gan To Kagaku Ryoho 2004; 31 (11): 1705-7
44. Carr BI, Dvorchik I. Effects of cisplatin dose intensity on response and survival for patients with unresectable and untransplantable hepatocellular carcinoma: an analysis of 57 patients. Gan To Kagaku Ryoho 2000; 27 Suppl. 2: 432-5
45. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88 (9): 1986-91
46. Court WS, Order SE, Siegel JA, et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002; 20 (5-6): 613-25 (Pubitemid 37210031)
47. Kajanti M, Rissanen P, Virkkunen P, et al. Regional intraarterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study. Cancer 1986; 58 (11): 2386-8 (Pubitemid 17191595)
48. Yoshikawa M, Ono N, Yodono H, et al. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008; 38 (5): 474-83 (Pubitemid 351593948)
49. Yamashita YI, Taketomi A, Itoh S, et al. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IAcall(®) in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009; 65 (2): 301-7
50. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378-90
51. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1): 25-34
52. Bayer. Nexavar approved in Japan for the treatment of advanced liver cancer [online]. Available from URL: http://www.onyx-pharm.com/view.cfm/589/ Nexavar-Approvedin-Japan-for-the-Treatment-of-Advanced-Liver-Cancer. [Accessed 2011 Jan 25]
53. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99 (1): 159-65 (Pubitemid 350239045)
54. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3): 205-16 (Pubitemid 30099779)